INS and type 2 diabetes mellitus: However, neither mice administered long acting analogs of GIP1–42[42], [43] nor GIP-overexpressing transgenic mice [53] exhibit increases in body weight, food intake, adiposity or insulin resistance, questioning whether GIPR agonists would promote obesity in patients with type 2 diabetes.